Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Victoria's Secret & Co — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Victoria's Secret & Co trades at $76 (market cap $6.26B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.4× Victoria's Secret & Co's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Victoria's Secret & Co nearer its low. Which is the better fit depends on your goals.
| VRTX | VSXY | |
|---|---|---|
Market Cap | $134.06B | $6.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $99.97 |
52-Week Low | $376.62 | $25.56 |
Enterprise Value | $128.18B | $8.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with a 45.27% ROE and improving cash flow projections. Recent news highlights PINK brand growth and beauty segment acceleration, though the stock faces near-term pressure from sales concerns despite earnings outperformance.
The outlook remains cautiously optimistic with a $97.33 consensus price target representing 24% upside potential. Key opportunities include sustained PINK growth and margin expansion, while risks involve competitive pressures and execution challenges. Analyst consensus leans bullish with 60% buy ratings, but investors should monitor Q3 2026 results for confirmation of the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
